BiologicalDrug
F8 protein, human clinical trials
Includes 26 studies of Antihemophilic factor, human recombinant.
Keep track of what changes. Save the F8 protein, human studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 1 |
| 2006 | 4 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 9
Baxalta now part of Shire (15) · Bayer (9) · Children's Hospital Los Angeles (1) · Oregon Health and Science University (1) · Fondazione Angelo Bianchi Bonomi (1) · Novo Nordisk A/S (1) · CSL Behring (1) · Chulalongkorn University (1)
Often tested with
Tested in the same studies.
Factor VIII (3) · Vonicog alfa (3) · BAX 855 (2) · Factor VIII, von Willebrand factor drug combination (1) · Lonoctocog alfa (1) · Optivate (1)
Studies
Open first, then newest update. How each study uses F8 protein, human is read from its arms, and is right about nine times in ten.
Testing it · 36
- A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)RecruitingPhase 3TakedaNCT07129343Written as ADVATE
- Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)RecruitingPhase 4Runhui WUNCT06864975Written as Advate®
- A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT02932618Written as Antihemophilic Factor (Recombinant)
- A Study of ADVATE in People With Hemophilia A in IndiaCompletedPhase 4Baxalta now part of ShireNCT04985682Written as ADVATE
- Preventing Inhibitor Recurrence IndefinitelyActive, not recruitingPhase 4Children's Hospital Los AngelesNCT04621916Written as FVIII
- Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing SurgeryCompletedPhase 2/3Baxalta now part of ShireNCT00157105Written as Antihemophilic factor, recombinant, manufactured protein-free
- Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901CompletedPhase 2/3Baxalta now part of ShireNCT00157053Written as Antihemophilic factor, recombinant, manufactured protein-free
- Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00289536Written as Antihemophilic factor, recombinant, manufactured protein-free
- BAX 855 Pediatric StudyCompletedPhase 3Baxalta now part of ShireNCT02210091Written as Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
- Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for InjectionCompletedPhase 1Baxalta now part of ShireNCT00952822Written as Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
- Early Prophylaxis Immunologic Challenge (EPIC) StudyTerminatedPhase 3Baxalta now part of ShireNCT01376700Written as Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
- Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)CompletedPhase 2/3Baxalta now part of ShireNCT01736475Written as Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
- Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT01410227Written as Recombinant factor VIIII (rFVIII)
- Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00243386Written as Antihemophilic factor, recombinant, manufactured protein-free
- Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00916032Written as Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
- BAX 855 Dose-Escalation Safety StudyCompletedPhase 1Baxalta now part of ShireNCT01599819Written as Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
- China ADVATE PTP StudyCompletedPhase 4Baxalta now part of ShireNCT02170402Written as Octocog alfa (recombinant human coagulation factor VIII)
- Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia ACompletedPhase 2/3Baxalta now part of ShireNCT00157040Written as Antihemophilic factor, recombinant, manufactured protein-free
- Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. NaiveWithdrawnNot applicableCity of Hope Medical CenterNCT01051544Written as FVIII Concentrates
- Prospective Biomarkers of Bone Metabolism in Hemophilia ACompletedPhase 3Oregon Health and Science UniversityNCT02306694Written as Advate
See all 36 studies that test F8 protein, human →
Given in every arm · 10 — F8 protein, human is usual care beside what is tested
- A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)RecruitingPhase 3TakedaNCT05582993Written as ADVATE
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ACompletedPhase 1SanofiNCT05042440Written as Octocog alfa
- A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT03879135Written as rFVIII
- A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionCompletedPhase 1Jiangsu Gensciences lnc.NCT04864743Written as ADVATE
- A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for InjectionCompletedPhase 1Jiangsu Gensciences lnc.NCT05251090Written as ADVATE
- A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)CompletedPhase 1/2Bioverativ, a Sanofi companyNCT03205163Written as Advate (Low Dose)
- rVWF IN PROPHYLAXISCompletedPhase 3TakedaNCT02973087Written as Antihemophilic Factor (Recombinant)
- BAX 826 Dose-Escalation Safety StudyCompletedPhase 1Baxalta now part of ShireNCT02716194Written as Octocog alfa
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia ACompletedPhase 3Bioverativ Therapeutics Inc.NCT01181128Written as Advate®
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia ACompletedPhase 3Bioverativ Therapeutics Inc.NCT01458106Written as FVIII (PK subgroup only)
As the comparator · 6 — what is tested is compared with F8 protein, human
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseRecruitingPhase 3Hoffmann-La RocheNCT06998524Written as Factor VIII (FVIII) Concentrates
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia ARecruitingPhase 3Hoffmann-La RocheNCT07416526Written as Human Coagulation Factor VIII
- Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00666406Written as Recombinant Factor VIII (rAHF)
- Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia ACompletedPhase 2OctapharmaNCT00989196Written as Kogenate FS
- Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980CompletedPhase 1BayerNCT00629837Written as Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia ATerminatedPhase 2BayerNCT00623727Written as rFVIII-FS/WFI (BAY14-2222)
Codes
What other systems call F8 protein, human · ClinicalTrials.gg INT003681
- MeSH (NLM) C078147F8 protein, humanOne source NLM
- UNII (FDA) 839MOZ74GKANTIHEMOPHILIC FACTOR HUMANConfirmed FDA, NLM
- RxNorm 826070One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C078147 | F8 protein, human | One source NLM |
| UNII (FDA) | 839MOZ74GK | ANTIHEMOPHILIC FACTOR HUMAN | Confirmed FDA, NLM |
| RxNorm | 826070 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.